Showing results (91-100 of 117) with videos related to
Sort By:
Pageof 12
Cancer Medicine|June 14, 2021
Preinfection laboratory parameters may predict COVID-19 severity in tumor patientsAlexander Kiani, Romina Roesch, Clemens M Wendtner, et al.Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.Neurology|October 11, 2013
Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group reportJennie W Taylor, Eoin P Flanagan, Brian P O'Neill, et al.Frontiers in Immunology|December 11, 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patientsJonas S Heitmann, Susanne Jung, Marcel Wacker, et al.Neuro-Oncology|February 9, 2021
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)Ramon F Barajas, Letterio S Politi, Nicoletta Anzalone, et al.BMC Cancer|August 18, 2023
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trialLisa K Isbell, Roswitha Uibeleisen, Alexander Friedl, et al.Journal of Neuro-Oncology|July 20, 2002
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisKurt A Jaeckle, Tracy Batchelor, Steven J O'Day, et al.Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.Blood|September 26, 2018
Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.Pageof 12